experiences pleased thanks The Annual to American in Chicago, us just Academy for very good quite Thanks, today. among I'm Meeting generally is positive. significant the just Rhopressa everybody joining gaining Having Ophthalmology And been of Rich, attention and have the report afternoon, that returned from prescribers.
other to only won't clearer Now much inadequate or That's with lowering. expected. pretty events tolerate to IOP will as products, patients be be be experience it certain that glaucoma adverse will
to works. We key kinase Rho or top differentiator learn and new inhibitors how ocular drugs more about of continue ROCK more of Rhopressa A on categorized and exclusively for Rhopressa for being hypertension. glaucoma class in inhibitors
increase in eye. that released statistically baseline. main tubercular outflow As may approximately Study, Rhopressa, observed to August meshwork. of year outflow remember Action results significant increase over the through And of Rhopressa, to Earlier that's this be XX is XX% Mechanism the our a of facility where of we grain specifically you line exact designed trabecular in fluid top
with animal in actually the different confidence gained diagnosed many doctors drug's on in we development unmedicated Rhopressa. This just of product. the what study Rhopressa this with of study patient we is the in data is of with example pretty activity, patients It many have baseline And was that to their is preclinical Now, that believe all consistent to the or research one ocular particular is now we in further doctor in usual performed Mercury. saw happening marketplace early to to XX pressures expanding this this scenarios. of an is hypertension kind do glaucoma of the XX characterize and continue the more millimeters
other drug. the they we as X,XXX migrating And practice. like tolerate are to do have therapies written thought Then other Ultimately, in that to course of on to adding patients a get who will a have a Rhopressa prescribing they and make already in pressure. with further top two patient. start of a be much are three analog several perhaps Bromadioline where do just therapies at intraocular glaucoma products are hundred its other practice we just a would But doctors of on that by the products gain drop Rhopressa. prostaglandin removing within to on scripts. as to of who their other load we it there'll for addition well. growth don't single each too physicians or have optimistic three basis. Rhopressa over of far, use itself We that experience two continue these that, decisions most or day top it times or prostoglandins Thus top use some Rhopressa, Each those some times particularly prescribed use Now of them of putting organic see And patient-by-patient come. on they prescribers
Now point I want a out to of things. couple
has First number particular X,XXX of all, that the this about have, last prescribers grown that three over months. we'd XXX%
of writing young territories targets, base of of in a where reps, a at New we Hampshire many all in the are top of Rhopressa out these in where prescribers those doctors got eight Rhopressa. and very XX% all that And or already writing his prescribers, already man of now high-decile country right we and to seven a territory the have continue writing where prescriber We've one that the of around targets highest of eight, their for deciles XX are Rhopressa. in the so, XX% of the and the of have them per we territories do Hawaii, couple all prescribers, fact, grow nine is
a we So couple the success is of top pretty the top territories widespread. – At the five reps. five have
of out is call We other as mentioned on out and two one I is California in them right the have do Northern Chicago. And them Manhattan. Hawaii. last one, out the have of of of in We one
as to see expect grow continues to product So, kinds these acceptance. successes continue to in we of the
patient in is ability said element market performance our we've of to as one our to a Now, population times, addition in gain success Rhopressa many important long-term access.
XX% of including and in XX% covered, we three. two XX% October now in of As tier tier X, commercial lives have
Importantly, gaining access on strides we’ve made excellent D Medicare Part side. in the
the to universe tier practice to the The administrative other about. yet XX% to half If increasing two our use which create we of offices and aren't success. always is worry expensive a a By are have doctors prior XX% coverage talked the will can had covered, is This around somewhere the the burden, our in patients many progress to we being previously up authorization critical in burden processes, that on that about often patients. cases coverage and
approval coverage authorizations averaging which and have prior other course Now, have in drugs is regardless for from excess XX% for thousand several been of need to plans experienced we've managed rates authorization been far the these range, seen as there that increases launch-to-date, care prior authorizations submitted decreases. of our for have what and Rhopressa
as Part looking the preferred two forward, expect have majority which covered support brand enter Now we would to tier Medicare D commercial prospects. our further both in XXXX, the and we of growth
we per particularly as revenue bottle pick have bottle payers up do roughly to in coverage, Now we was tier per in $XXX to $XXX QX. net net bottle the was rebates as two, a It down. that pay in revenue our That reminder, QX. per bring
it will coverage, pick level-off. ultimately we up As more
net to $XXX will As get we prices bottle, where be. approach and close which end per year that of to about the estimated consistent we've is the the always
of that our adoption terms trajectories press little As advances in we you guidance million our more release, physician detail sales the on access for of methods our with are net million reiterating we bit on gaining based saw ensure in of go market to or XXXX. a to numbers. comfortable Rich we $XX that will $XX in our into feel look kind
recognizing months eight we available. times, folks we we heard That's have one the things And maintain want for that say inventories our are many no outs. in currently so strong on include channels, for demand Now there. does of wholesalers Rhopressa that numbers no to in make we're inventory hand our stock me what or enough in that ourselves. And retail that manufacturing there warehouses, trade just supply of have Rhopressa, sure we have the not or about
So, have enough meet continues, in to we product more will as the demand. the uptake than order
our early we get be manufacturer expect there'll in hand second get that us. early approval, on assuming also XXXX, begin us, a have supplying supplier they second to or for they contract Rhopressa, approval Now providing
also this we're we have is We want market of Now because our flexibility on side, critical de-risked have market. the sure the going obviously that we're and to have on manufacturing Rhopressa can supply so gonna a make maintain, on lot that we sourcing. the Rocklatan to
on in own progress our addition Ireland track, they've I'm proud to Now facility made. the that of that proceeding very
the not was was plant actually firsthand, progress. first a just couple I I that manufactured ago, weeks too And that actually I they the day at just fact, visited to it received made ago there. have year long the was actually one it incredible In site. saw and I bottle that of
So, very, special it's team. very for occasion that a
Our fully an to already sales. but XX% start supply our to control Ireland of resulting sourcing, starting and our ability in Rocklatan early estimated in have We'll plan with XXXX. in only is not commercial low secure also in first reduction cost
public in of the we the same. discussed one City ago, and was you were just companies the research couple were products important Now, nominated the give introduced that XX There Galien market right well agent. in we us year that to functions. for into previously. achievements pharmaceutical the pharmaceutical large we at to didn't most teams field. of Award New large on were the Rhopressa Many Galien best incredibly as win, as haven't awards was Rhopressa Most of just contenders the with pharmaceutical nominated by the drugs the and a best know this of event point Prix last innovative were research while credit the York weeks as AAO, front in honored the Foundation
team was Now five a bench. for Rhopressa guys on the scientists, molecule netarsudil developed by the the seven us, including of
very proud achievement. of we're that So
to move second. on Let's for a Rocklatan
to commercial rapid a forward of look post very approval. to year advance set next team our date that provide trained we to sure well our in make continue fully hope launch We is for and what to PDUFA mid-March be
use same Now the salesforce Rocklatan. managers remember XXX commercialize of territory to we'll
have right sure add asked Rich the Now many of regulatory k naming noticed we after approval Rocklatan, have and process you the gone through c. but I'm a they've name probably called us to us the about and and drug misspelling
that not well performing Rocklatan extraordinary prostaglandin. is there’s a So as a how to once level again it's Rhopressa that's in think that on. from now to be stems the misspelling. added interest will appears Rocklatan, is AAO, of the we from That be no, spelled when at There interest confirmed an way
predict. doctors to it's I've mentioned the split I think asked we and so how going going prescribe And to have think very would to is be what Personally, versus before. Rocklatan that many difficult Rhopressa be.
doctors the will perspective, significant acceptance, in the think the we consistently path us marketplace. their I own a From a in access. basis. pricing if Rocklatan the which believe the a It's market we when approved, patient-by-patient to ultimately and write clear however, fairly with Rhopressa, on very necessary will follow price in market including to Rocklatan expect do have gains potential
to Agency outside Medicines European Now October, MMA, Rhopressa early initiatives seen turning authorization the marketing our that you we in for U.S., Europe. for is may the our accepted Rhokiinsa. have That name our the application announced in at
would review. take we approval, will and months months to a expect review. approximately we go We And XX after Rocklatan another that for then the that'll XX through file it immediately that get be
plans Europe changed. Our in haven't
purposes Rocklatan ophthalmology commercialize key end to expect our top the European Europe Also, Europe, which first we X have very our in been of underway and We've by We active trial to and data Mercury expect in we beneficial the for be should line forums. XXXX, currently in pricing European the own. for countries. conferences on in
and of we attended Congress in meeting & year attended Society Glaucoma the Vienna Milan. We have Surgeons European recently Cataract Refractive European that this was in Society earlier
Ireland. Aerie, have employees We have They managed operation we XX interest build of facility this in manufacturing an have in lot of to awful our noted, important growing now over there's in an Europe. And in region.
our employees that, clinical I X medical to the on clinical, just a of and an with have in addition number build for in Mercury execution the incremental started affairs Europe mentioned. And we of only In focused commercial Europe. not we just teams trial
the X you Japanese a in even Japan. then and and provide if addition Japanese the and move of are we also more X progression trials prepare Phase now for Japanese going X importantly, perhaps trial. stage programs access for which be onto higher in Phase into Phase Phase to to our level patient in we – enroll set to the done American and a Rhopressa, the in activities market, as X of for availability the trial to remember, We're we trial our patients much the mainland, trial Japanese really a Now expanding clinical
a We office clinical activities to oversee small have and Tokyo our regulatory in established in Japan.
just Japan few that a growing the to then number weeks in and lot chance awful think of the ago some that. there's do with I Rhopressa of a personally, like meet country. of and an that Now I interest had KOLs a interviews And in and things
looking Now we the ahead charging pipeline, at retina with product preclinical for two market. are our our candidates
of to several in the couple these there is which AR-XXXX. as is preclinical glaucoma treat shown for product larger when reminder, years here are standalone market-leading acquired and this macular that kinase unmet bought new well. We dexamethasone The an the significant advancing activities efficacious ability experiments, basis is this U.S., and a therapies molecules, AMD. it's degeneration market to of also potential market. about program AR-XXXXX are and as over rights space retina both Rho-kinase The in pathway as products well a remember both steroid XXX, the As are enthusiastic for treatment believe as DME each both a We're you macular new protein as potential. preclinical efficacy that than in the to think very or is DME. we efficacy the edema a larger we diabetic wet completely provide may wet we Envisia, We're diseases. part for inhibits which on treating age for XXXX, one Eylea, that believe they have related And months. the adjunct implant ago, AR-XXXX being additive sustained that to needs AR-XXXXX, period a And the C. is relative we ongoing we or couple candidates’ know, to a And is
Our collaboration as such capabilities our sustained molecules gain an AR-XXXXX. release provide through long-term small DSM opportunity exciting for to
also Now exclusive through and implants sizes have very implant ophthalmic rights technology. ocular to to manufacturing we've a make precise our PRINT manufacturing in shapes platform
provide of we you weeks implants established validated time floor the couple product a filing North candidates, XXXX. all be GMP fact, We in sustained principally this the in may early headquarters. and end clinical do ago, space. our will plan the retina In mere seen our for of facility year, PRINT of have release XXXX used around square our to our We're Facility development programs. the Durham, where Production in using feet all for this AR-XXXXX Carolina announcement, This of on for IND for AR-XXXX
combination worldwide have as enter we license their program all technology for exclusive release a of and the only the the to to where manufacturing not the front unlimited This space, indications for our including unique sustained with of the products build XXXX. candidates very on our With is believe with in We expect retina eye, We DSM, DSM succeed to collaboration innovative, use compounds. both of potential platform. a platform provide we opportunity this step to using delivery important sustained innovate expanded also retina ophthalmic clinic company PRINT our but platform the is believe continue now for what in company we number glaucoma. and agreement an highly later to to
of features you Rho-kinase that and molecules, Finally, own may address each additional we as beyond ultimately a attributes eye. know, the unique do diseases library with
these clinic or us through is including it take on dermatology value begin uses, asthma opportunities pulmonary our mentioned into I partners, of any own, our are our evaluating understand of last We and call, academic to other for but diseases, on proprietary won't certain incumbent our As the necessarily on indications. to we in institution own medical full library.
you as We progress make of will business. back and to our as report we continued part
I'll over to Now turn Rich? cover with that, Rich back financials. it the to
